0.2050USD+11.11%Mkt Cap: 1.62M USDP/E: —Last update: 2026-05-29
ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It develops drug development platforms, including Cholest…
Industry Peers
Biotechnology111.39BUSDP/E 26.0
100.62BDKKP/E 19.4
62.97BUSDP/E 14.7
48.39BEURP/E 31.7
44.65BEURP/E 37.2
40.10BUSDP/E 75.3
35.22BUSD—
32.91BSEKP/E 48.6
Indicators:|
Key Statistics
Company
Market Cap1.62M USD
Enterprise Value2.56M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-24.95M USD
Revenue/Share—
Last Price0.2050 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees6
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.04
PEG—
EV/EBITDA—
EV/Revenue—
P/S—
P/B-0.14
EPS (TTM)-3.67
EPS (Forward)-4.80
52W Range
0.11006% of range1.670
52W High1.670 USD
52W Low0.1100 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE201.44%
ROA-7172.26%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-5.11M USD
CapEx (TTM)—
FCF Margin—
FCF Yield-128.44%
Net Debt897.34K USD
Net Debt/EBITDA—
Balance Sheet
Debt/Equity—
Current Ratio0.05
Quick Ratio0.02
Book Value/Sh-1.4480 USD
Cash/Share0.0370 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split1:10
Split DateApr 26, 2024
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.8.10M
Float7.68M
Insiders0.02%
Institutions5.15%
Short Interest
Short Ratio0.3d
Short % Float7.38%
Short % Out.7.37%
Shares Short359.25K
Short (prev mo.)300.95K
Technical
SMA 500.2022 (+1.4%)
SMA 2000.1766 (+16.1%)
Beta—
S&P 52W Chg27.70%
Avg Vol (30d)10.37K
Avg Vol (10d)5.81K
Technical Indicators
RSI (14)51.6
MACD-0.0050
MACD Signal-0.0057
MACD Hist.+0.0007
BB Upper0.2223 USD
BB Middle0.1953 USD
BB Lower0.1683 USD
BB Width27.64%
ATR (14)0.0266 USD
Vol Ratio (20d)1.75x